A phase 111 prospective randomized multicenter study was performed t o determine whether quinine could improve the response rate of poor-risk acute leukemias (ALs) t o standard chemotherapy including a multidrug resistance (MDR)-related cytotoxic agent. The rationale of the study was based on the negative prognostic value of MDR phenotype in ALs and the ability of quinine t o reverse this phenotype both in vitro and ex vivo. Three hundred fifteen patients (median age, 49 years; range, 16 t o 65) with relapsed (n = 108) or refractory (n = 32) acute myeloblastic leukemia (AML), relapsed (n = 27) or refractory (n = 9) acute lymphoblastic leukemia (ALL), secondary AL (n = 22) or blastic transformation of myelodysplastic syndrome ([MDS] n = 74) or myeloproliferative syndrome ([MPS] n = 4 3 ) were randomly assigned t o receive mitoxantrone ([MXNI 12 mg/m2/d, days 2 t o 5) and cytarabine ([Ara-Cl 1 g/m2/12 h, days 1 t o 5) alone or in combination with quinine (30 mg/kg/d, days 1 t o 5; continuous intravenous infusion beginning 24 hours before MXN infusion). Side effects of quinine were observed in 56 of 161 quinine-treated patients and disappeared in all but four cases after one or two 20% dose decreases. Sera from T HE MAIN REASON for the failure of conventional regimens combining an anthracycline or an aminoanthraquinone with cytarabine or etoposide for the treatment of acute leukemias (ALs) is the primary or secondary resistance of leukemic cells to cytotoxic drugs. According to the Goldie and Coldman' hypothesis, these regimens select drugresistant clones that develop by spontaneous mutation or tumor cell adaptation. In vitro cell culture systems have identified several mechanisms of cellular resistance to cytotoxic drugs. One of these mechanisms is characterized by the multidrug resistance (MDR) phenotype that is associated with increased expression of the mdrl gene product, called Pglycoprotein, in the leukemic cell plasma membrane.' This increased expression has been identified in clinical samples, mainly from relapsed and refractory ALs, and related to a lower response rate to conventional treatment and a shorter event-free survival and overall ~urvival.~" The decreased intracellular accumulation of a variety of cytotoxic agents, characteristic of the MDR phenotype, can be reversed effi- 0 1996 by The American Society of Hematology. 0006-4971/96/8804-0020$3.00/0 1198 quinine-treated patients showed increased MXN uptake in an MDR-positive cell line compared with matched sera obtained before quinine infusion. Quinine induced a significant increase in the incidence of nausea, vomiting, mucositis, and cardiac toxicity. A complete response (CR) was observed in 85 of 161 patients (52.896) from the quinine-treated group versus 70 of 154 patients (45.5%) in the control group (P = .19). The most important differences between quinine and control group CR rates were observed in patients with refractory AMLs and blastic transformation of MDS and MPS. The CR rate was higher in P-glycoprotein-positive cases, although the difference was not significant. Failure of the regimen due t o blastic persistence or blast number increase was higher in the control group (61 of 154 patients) than in the quinine group (45 of 161, P = ,041. Early death was observed in eight cases (four in each arm) and death in aplasia in 27 cases (20 in quinine group Y seven in control group, P = .01). The significant increase of toxicity in the quinine arm could have masked the clinical benefit of MDR reversion in poor-risk ALs.
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ciently in vitro by a number of noncytotoxic agents.'"' The in vivo use of most of these agents is precluded by serum protein binding or clinical toxicity,"," and circumvention of the MDR phenotype has not yet proven clinically useful.
We previously showed that intravenous infusion of conventional doses of quinine allowed attainment of a sufficient concentration in serum to reverse the anthracycline resistance of rat colon cancer cells and MDR human leukemic cells.'J~15 Then, we defined the conditions for the use of quinine as a MDR modifier" and performed a phase 1/11 clinical trial to demonstrate that quinine could be used safely in combination with mitoxantrone (MXN) and cytarabine (Ara-C) for the treatment of clinically resistant ALS.'' Here, we report the results of a phase I11 multicenter clinical study designed to answer the question of whether the response rate of poor-risk ALs to conventional chemotherapy could be improved by quinine. In this trial, patients with either relapsed, secondary, or refractory AL were treated with a combination of MXN and high-dose Ara-C. After randomization, half the patients also received quinine as a potential MDRreversing agent.
PATIENTS AND METHODS

Patients.
The study was an open phase 111 prospective randomized trial with 15 participating medical centers, performed from March 1992 to February 1995. The protocol received approval from the ethics board of the Dijon hospital. Before therapy, all patients provided informed consent after having been advised about the purpose and investigational nature of the study, as well as potential risks. Patients eligible for the study were older than 14 and younger than 66 years, with a bone marrow diagnosis of acute nonlymphoblastic or acute lymphoblastic leukemia (ALL) as defined by the French-American-British classification system." These patients ei- For personal use only. on October 27, 2017. by guest www.bloodjournal.org From ther had relapsed from or were refractory to standard first-line chemotherapy. Refractory patients were defined as those with de novo AL failing to achieve complete remission (CR) after one or two cycles of chemotherapy. Relapsed patients included those with acute nonlymphoblastic leukemia or ALL who achieved a previous CR with a standard therapeutic regimen, which sometimes included autologous or allogeneic bone marrow transplantation. Patients with secondary leukemia or blastic transformation of myelodysplastic (MDS) or myeloproliferative (MPS) syndromes were also eligible. Other eligibility criteria included adequate kidney and hepatic function (creatinine <250 pmol/L, serum bilirubin < 14 m&, and transaminases <4N), adequate cardiac ejection fraction as measured by echocardiography (>30%) or radionuclide ejection (>50%), and cumulative dose of anthracycline less than 400 mg/m2 adriamycinequivalent. Patients with recent myocardial infarction or vascular cerebral infarction and those with known hypersensitivity to quinine were ineligible. Random permuted blocks of 10 were used to generate the randomization list. No stratification was used. All randomizations were performed by the Clinical Hematology Unit of the Dijon hospital. The data were collected centrally by this office and were subsequently reviewed by three clinicians.
Regimen. The therapy regimen consisted of Ara-C 1 g/m' administered by 2-hour intravenous infusion twice daily on days 1 through 5 and MXN 12 mg/m' as a 30-minute infusion on days 2 through 5. After randomization, half the patients received quinine formiate (Quinimax; Labaz Laboratories, Paris, France) at a dosage of 30 mg/kg/d started 24 hours before the first dose of MXN and administered as a continuous intravenous infusion until 24 hours after the end of the last MXN infusion. Toxicity was assessed according to the World Health Organization (WHO) grading system. CR was defined by the presence of less than 5% leukemic blast cells in the bone marrow, their disappearance from the blood and possible extramedullary sites, including the cerebral fluid, and an increase of the peripheral granulocyte count to greater than 1,00O/pL. Partial response was defined by a percentage of bone marrow blast cells less than 25%, a percentage of peripheral blood blast cells less than 5%, and peripheral blood granulocyte count higher than l,OOO/pL. In patients in CR, the duration of critical cytopenia was evaluated by the time required for leukocyte (>500/pL), granulocyte (>500/ pL), and thrombocyte (> 100,OOO/pL) recoveries and the red blood cell transfusion requirement (hemoglobin <80 g/L) from the onset of treatment.
Quantzjication of quinine concentrations in semm. Total quinine concentrations were determined as previously described.18 Patient serum was mixed with 0.5 mol/L borate buffer, pH 9.8, and hydroquinidine as internal standard. Extraction was performed with a mixture of dichloromethane and isoamylic alcohol (98:2 vol/vol). After centrifugation, the organic phase was evaporated to dryness, dissolved in the mobile phase (potassium dihydrogen phosphate 0.045 moUL, acetonitrile 4:1 vol/vol, pH 3.8), and injected into the highperformance liquid chromatography (HPLC) apparatus equipped with a U6K injector and a M45 pump (Waters Associates, SaintQuentin-en-Yvelines, France). The column was a Nova-pak C18 (150 X 3.9 mm, 5 pm). Detection was made with a FP 210 spectrofluorometer (Prolabo, Vaux-en-Velin, France) with excitation and emission wavelengths of 350 and 440 nm, respectively. Retention times were 2.4 and 3 minutes for quinine and hydroquinidine, respectively.
Ex vivo assay. To determine the ability of serum from quininetreated patients to increase the MXN intracellular concentration by reversing the MDR phenotype, we designed an ex vivo flow-cytometry assay using the CEMNLB human leukemic cell line (Genne et al, manuscript submitted). This cell line overexpressed both mdrl mRNA and P-glycoprotein (not shown). CEMNLB cells (2 x IOs)
were seeded in microtiter plates (24 wells/plate) and cultured for 24 hours, and then incubated for 2 hours at 37°C with 20 pmoUL MXN diluted in serum samples obtained from patients either before or 2 days after the beginning of quinine infusion. After a 2-hour incubation, cells were rinsed three times with ice-cold phosphate-buffered saline and resuspended in phosphate-buffered saline (PBS) for measurement of MXN intracellular accumulation, using a Becton Dickinson (Pont de Claix, France) FACScan flow cytometer at an excitation of 488 nm and an emission of 675 nm.
Detection of P-glycoprotein. P-glycoprotein expression was determined using MRK16, a monoclonal antibody that recognizes the extracellular determinant of P-glycoprotein (Immunotech, Luminy, France), and a previously described indirect immunofluorescent assay." Briefly, cells were fixed in 1% paraformaldehyde for 30 minutes at 4°C and incubated in human AB serum before a 30-minute incubation with MRK16 antibody (2 pg/mL), and then with fluorescein-conjugated F(ab'), fragments of goat anti-mouse IgG (37.5 pg/mL; Silenius Laboratories, Paris, France). The percentage of positive cells was determined by cytofluorimetry on gated blast cells using a Becton Dickinson FACScan flow cytometer. A nonrelevant IgG2a (Coulter, Raritan, NJ) was used with the same goat antimouse second-step reagent to calibrate the assay on the FACScan and determine the positivity for individual cells. P-glycoproteinpositive K562/ADM cells were used as a positive control. Various cutoff values for positivity were tested.
Statistical analysis. According to previous studies, the CR rate induced by the MXN-Ara-C regimen was approximately 50%.19-2 ' The study was designed to detect a 20% improvement in the CR rate (two-sided test) with a significance level of .05. A total of 137 patients per treatment group was calculated to be necessary to reach this goal, which was expected to require 3 years. At the time of statistical analysis, categorical data obtained from the patients before treatment and their response rates were compared by the x ' test or Fisher's exact test in cases of small expected values. The MantelHaenszel test was used for adjustment of the results for the sex imbalance. The t test for nonpaired samples was used to compare quantitative parameters. A two-way ANOVA was performed to compare hepatic enzymes and bilirubinemia changes during treatment in both arms of the trial. A stepwise logistic regression model was used to assess the joint effect of prestudy variables on response. Validity of the model was evaluated by the Homer-Lameshow test. Statistical analyses were made with either Statview (Alsyd, Meylan, France) or BMDP software systems.
RESULTS
Characteristics of patients. From March 1992 to February 1995, 328 patients entered the study. Data were obtained from 318 patients. One patient was not eligible (diagnosis error), and two were not assessable (one did not receive the treatment, and the other died after randomization and before treatment onset). Three hundred fifteen patients were assessable: 161 received quinine, and 154 were treated without quinine. Despite the lack of stratification at initial randomization, the two arms of the study were well balanced in the 15 centers. Initial diagnoses of these assessable patients and their pretreatment characteristics are summarized in Table   1 . MPSs included chronic myelogenous leukemias (n = 32), polycythemia vera (n = 6), essential thrombocytemia (n = 3), and myelofibrosis (n = 2). The only significant imbalance in the pretreatment variables was the higher number of women in the control arm ( P = .03). Analysis of response rates was adjusted for this imbalance.
Serum quinine levels and MDR-reversing activity of sera. Serum samples from 40 patients (n = 20 per treatment arm)
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From were tested before and at day 2 of treatment. In quininetreated patients, sera obtained on day 2 showed increased MXN uptake in CEMNLB cells compared with matched sera obtained before treatment (mean k SD, 43% 2 30%; range, 13% to 117%). The mean concentration of quinine in these samples was 6.5 pg/mL (range, 1.5 to 13.0). When tested under the same conditions, sera from control patients did not demonstrate any significant effect on MXN accumulation (data not shown). When various concentrations of quinine were added to a control serum, a linear relationship was observed between quinine concentration and MXN uptake in CEMNLB cells incubated for 2 hours in this serum (R2 = .97, P = .0003; Fig 1A) . The same experiment was per- Quinine serum level (pglml) decrease. In four patients, an additional 20% dose decrease was necessary. In the last four patients. quinine infusion was stopped after day 2 (one patient) or day 3 (three patients), due to an excessive QT interval increase or bradycardia. The mean age of patients who demonstrated hearing loss was significantly higher than the mean age of patients who did not report a hearing change (53.5 5 13 1'44.2 ? 14.2 years, P < .OS). No relationship was found between side effects and other pretreatment characteristics of patients. In quininetreated patients, the occurrence of quinine-related side effects was associated with a significant increase in the time to discharge from hospital (37.8 ? 11.7 11 31.4 ? I I .0 days, P < .0008) and leukopenia duration (27.7 ? 1 1.4 1' 22.3 ? 8.7, P = .02). By contrast, no difference was observed between quinine-treated patients who did not receive quinine and the control group.
Nonhematopoietic toxicity.
The nonhematopoietic toxicity associated with the regimen is reported in Fig 2. Quinine infusion significantly increased the incidence of nausea, vomiting, and .mucositis. The duration of these side effects was slightly increased in quinine-treated patients, but the differences did not reach significance. By contrast, quinine had no influence on renal and hepatic toxicity and did not induce a significant increase of bilirubinemia. Although cardiotoxicity was reported in only six patients during quinine perfusion, late toxicity (mainly cardiac failure) was observed in 10 additional patients from the quinine arm. compared with two patients from the control arm ( P = .03). Twelve of 16 patients who demonstrated cardiotoxicity were older 1201 than 50 years. In six patients, cardiotoxicity was reported in the absence of previous anthracycline treatment.
Hrntatologic toxicity.
Among responding patients, quinine slightly increased the median time to leukocyte recovery over SOO/pL, granulocyte recovery over 500/pL, platelet recovery over 50.000/pL. and hemoglobin recovery over 8 g/ dL (Table 2) . However, only the time to platelet count recovery in the relapsed AML group was significantly increased by quinine (mean, 35.6 2 12.5 v 29.4 ? 9.9 days. P = .037).
In this group of patients, quinine also significantly increased the mean time to discharge from hospital (38.1 ? 10.0 v 32.1 ? 10.0 days, P = .007). Seven responding patients from the control group and nine from the quinine-treated group never recovered a platelet count over 100 X I O 9 L Similarly. 13 responding patients from the control group and I I patients from the quinine-treated group required red blood cell transfusions for longer than 60 days. Quinine did not significantly increase the incidence of febrile episodes or aspergilloses (Table 2) .
Response to treatment. CR rates are listed in Table 3 . Univariate analysis indicated that the overall CR rate was associated with younger age. lower white blood cell count, and lower percentages of peripheral blood and marrow blast cells at diagnosis (not shown). When these parameters were entered in the logistic regression in association with quinine and sex, a higher CR rate was related only to age less than 40, lower white blood cell count, and lower percentage of marrow blast cells. The CR rate was higher in the quinine- For personal use only. on October 27, 2017. by guest www.bloodjournal.org From 45 .5%), but the difference was not significant ( P = .19). The estimated relative odds ratio of CR (quininekontrol) adjusted for sex was 1.32 (confidence interval, 0.81 to 2.00). Quinine significantly improved the CR rate in previously treated patients who relapsed after a first CR shorter than 18 months (42 of 76 patients in the quinine arm v 26 of 67 in the control arm, P < .05). In MDS and MPS, the CR rate was significantly improved by quinine when the delay from chronic phase to blastic phase was less than 48 months (eight of 14 patients in the quinine arm v 26 of 67 in the control arm, P < .05).
Failure of the regimen due to blastic persistence or blast number increase was higher in the control group (61 of 154 patients) than in the quinine group (45 of 161 patients, P = SOLARY ET AL .04). Eight patients died during treatment (four in each arm). Twenty-seven patients died in aplasia after day 7: seven were in the control group (refractory AML, one; relapsed AML, three; and blastic phase of MDS, three) and 20 in the quinine group (refractory AML, two; relapsed AML, six; relapsed ALL, four; secondary AL, two; blastic phase of MDS, three; and blastic phase of MPS, 3; P = .01). Postremission therapy was heterogeneous. The median duration of CR was 6.0 months and median survival was 11.5 months, without significant differences between control and quininetreated groups.
Relationships between response rate and P-glycoprotein expression. P-glycoprotein expression was determined on blast cells from 102 patients (control a r m , 47; quinine arm, 55) using MRK16 monoclonal antibody. Its expression ranged from 0% to 86% of positive cells. This expression was greater than 5% in 45 patients and greater than 10% in 30 patients, without a significant difference between treatment groups. The CR rate was higher in P-glycoproteinpositive cases at all tested cutoff values for P-glycoprotein positivity (Table 4) . However, these differences never reached statistical significance. Similarly, no relationship was found between either CD34 expression on blast cells or other biologic or clinical pretreatment parameters and the influence of quinine on the response rate (not shown).
DISCUSSION
Although there is evidence that MDR phenotype is a prognostic factor in ALs, the issue of whether P-glycoprotein is a useful therapeutic target is still unresolved. Combined therapy with MDR-related drugs and P-glycoprotein modulators prolonged the life span in some animal and en- and phase VI1 pilot studies.'6324 Here, we report the first large randomized trial that evaluates the clinical relevance of MDR reversion in ALs. Although this study failed to demonstrate a significant increase in the response rate for the quinine arm, several arguments suggest that MDR reversion could improve the efficacy of conventional treatments including an MDR-related agent. The most important effects of quinine on the response rate were observed in refractory AML and blastic transformation of MDS and MPS, which are also the most resistant ALs to conventional therapy. Moreover, quinine induced a significant decrease in the failure rate due to blastic persistence or blastic growth during treatment. Lastly, there was a trend for quinine to improve the response rate in P-glycoprotein-positive ALs. Therefore, quinine could be useful in a selected group of poor-risk leukemias that overexpress P-glycoprotein.
The lack of significant improvement in the overall response rate could be related to insufficient potency of quinine as MDR-reversing agent. Quinine and many other agents tested so far are first-generation chemosensitizers that have been developed for pharmacologic effects other than MDR circumvention. All these agents increase accumulation of MDR-related drugs in MDR-positive cells in Quinine also allows subcellular redistribution of doxorubicin in a MDR-positive leukemic cell line.26 Many of the potent reversing agents in vitro are too toxic in vivo at doses that mimic the conditions in vitro.13 Consequently, a number of studies actually used suboptimal concentrations. Even when the chemosensitizer plasma level is within the range of concentrations active in vitro, protein binding could limit its ability to reverse MDR in V~V O . ' * * '~*~~ The MDR-reversing activity of quinine is retained in serum despite serum protein binding. The ability of serum to increase MXN accumulation in a MDR-positive leukemic cell line was linearly related to quinine level in the serum of quinine-treated patients. Conversely, the ability of serum samples from control patients to reverse MDR phenotype did not increase during cytotoxic treatment (data not shown). However, quinine serum levels remained sometimes as low as 1.5 kg/mL at day 2 of continuous intravenous infusion. Tinnitus and vertigo are well-known complications of quinine administration whose appearance was previously related to the highest quinine serum levels.27 A significant relationship was observed between the occurrence of these side effects and the increased duration of neutropenia in responding patients. This later effect could be explained by either the reversion of Pglycoprotein function in bone marrow precursors28 or the alteration of MXN and Arg-C metabolism or excretion by normal tissues that express the MDR phen~type.'~ Only one third of the patients reported quinine-related side effects, suggesting that the quinine serum level could have been too low to efficiently inhibit P-glycoprotein in a majority of patients.
P-glycoprotein is expressed in endothelial cells of the central nervous system and is thought to contribute to the bloodbrain barrier.30 Therefore, the increase of nausea and vomiting in quinine-treated patients could be related to the increased distribution of MXN to the vomiting centers of the brain stem. Nausea and vomiting could also be the consequence of an increased drug exposure as an effect of quinine infusion on MXN pharmacokinetics in humans.29 Both verapamil and cyclosporin were reported to increase the plasma area under the curve of several MDR-related drugs in animals and Cinchonine, a diastereoisomer of quinine and a potent MDR-reversing agent in vitro and in vivo, did not modify doxorubicin pharmacokinetics in rat but modified the distribution of the cytotoxic drug in several tissues.33 Such a pharmacokinetic effect could explain the increased incidence of mucositis and could be involved in the increased cardiotoxicity of the regimen observed mainly in older patients.34 Whatever its mechanism, this significant increase in toxicity of the regimen could have masked the clinical benefit of MDR reversion, and better management of this toxicity could reveal the clinical advantage of the combination.
P-glycoprotein is expressed only in a subset of patients, and leukemic cells without P-glycoprotein should not respond to attempted modulation. Previous studies have shown that the number of P-glycoprotein-expressing cases was higher in poor-risk ALs than in de novo ALs.3-7.35 However, results are discordant from one study to another, depending on the disease and the technique chosen to identify MDR p h e n~t y p e .~~ Using MRK16 monoclonal antibody to detect P-glycoprotein in 102 assessable patients, MDR phenotype was identified in a limited number of cases, suggesting that only a minority of the quinine-treated patients could have been sensitive to MDR-reversing activity in our series of patients. Moreover, some P-glycoprotein-positive leukemic cells could not respond to quinine because of a lack of functional P-glycoprotein. The extent to which mutations and polymorphism of P-glycoprotein may confer altered binding specificity in leukemic cells is not known.37 Functional MDR phenotype was reported to be predominant in CD34+ leukemic cells, whereas P-glycoprotein could not be functional in CD34-cells.38 Nevertheless, no significant relationship was found between CD34 expression and the response to treatment in 136 patients in whom its expression was studied (data not shown).
Two other reasons could account for the lack of clinical benefit from quinine in the present study. Even when Pglycoprotein is present and functional, its inhibition could not be sufficient to render the leukemic cells sensitive enough to a MDR-related cytotoxic drug, due to the presence of other mechanisms of resistance in poor-risk A L s .~~ Accordingly, quinine and other reversing agents could be more potent in MDR-positive de novo ALs in which other mechanisms of resistance might be less present. Lastly, high doses of Ara-C were demonstrated to induce high response rates in poor-risk ALs.@ Ara-C is not involved in MDR, and identification of both MDR phenotype and resistance to Ara-C was shown recently to better identify the more resistant ALs.~' Therefore, the clinical benefit of quinine could have been masked by the efficacy of Ara-C.
Several recent randomized studies also failed to show any benefit of MDR-reversing agents, including quinidine and verapamil, in terms of response to chemotherapy or length of survival in patients with multiple myeloma, small-cell For personal use only. on October 27, 2017. by guest www.bloodjournal.org From lung cancer, and breast ~a n c e r .~~-~' These negative results should not prevent further trials that test the potential interest of these and more potent MDR-reversing agents in ALs. Better management of the regimen toxicity or the use of second-generation chemosensitizers that have been designed in this respectzs could improve either the response rate or the survival. While waiting for the possibility of testing new compounds in randomized controlled trials, the Groupe Est Ouest LeucCmies Aigues MyCloblastiques has initiated a phase 111 study in de novo AML testing the effect of quininemediated MDR reversion on survival.
